A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 51/10 (2006.01) A61K 47/48 (2006.01) A61P 35/00 (2006.01)
Patent
CA 2411102
Treatment of B-cell associated diseases including autoimmune and B-cell malignancies such as leukemias, lymphomas, using the combination of an anti- CD20 antibody, preferably RITUXAN® and a radiolabeled anti-CD22 antibody, preferably an 90Y labeled humanized anti-CD22 antibody, is described. These therapeutic regimens provide for enhanced depletion of B cells, and therefore reduce the risk in B cell malignancy treatment of relapse associated with RITUXAN® and, moreover, provide for prolonged immunosuppression of B-cell immune responses, especially in the context of autoimmune diseases and transplant.
La présente invention concerne un traitement de maladies associées aux cellules bêta comprenant les maladies auto-immunes à caractère malin telles que les leucémies, les lymphomes, par combinaison d'un anticorps anti-CD20, de préférence RITUXAN®, et d'un anticorps anti-CD-22 radiomarqué, de préférence un anticorps anti-CD22 humanisé radiomarqué ?90¿Y. Ces posologies thérapeutiques permettent d'obtenir une déplétion des cellules bêta, réduisant ainsi le risque de rechute associée à RITUXAN® dans le traitement de la malignité des cellules bêta, et permettant en outre d'obtenir une immunosuppression des réponses immunitaires, en particulier dans le contexte des maladies auto-immunes et des transplantations.
White Christine
Biogen Idec Inc.
Gowling Lafleur Henderson Llp
Idec Pharmaceutical Corporation
LandOfFree
Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2054496